Case Control Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Jan 7, 2022; 10(1): 35-42
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.35
Table 1 Comparison of therapeutic effects, n (%)
Group
Number of cases
Significantly effective
Improved
Ineffective
Total effective rate
Study group4729 (61.70)15 (31.91)3 (6.38)44 (93.62)
Control group4721 (44.68)16 (34.04)10 (21.28)37 (78.72)
χ2 value4.374
P value0.036
Table 2 Comparison of synovial membrane thickness and visual analog scale scores
Timing
Group
Number of cases
Synovial thickness (mm, mean ± SD)
VAS score (mean ± SD)
Before treatmentStudy group475.29 ± 1.447.01 ± 1.38
Control group475.50 ± 1.326.89 ± 1.50
t value0.7370.404
P value0.4630.687
After treatmentStudy group472.05 ± 0.592.11 ± 0.62
Control group472.87 ± 0.642.90 ± 0.79
t value6.4585.393
P value0.0000.000
Table 3 Comparison of blood flow classification, n (%)
Timing
Group
Number of cases
Grade 0
Grade I
Grade II
Grade III
Before treatmentStudy group4725 (53.19)12 (25.53)7 (14.89)3 (6.38)
Control group4723 (48.94)15 (31.91)5 (10.64)4 (8.51)
χ2 value0.1700.4680.3820.000
P value0.6800.4940.5361.000
After treatmentStudy group4736 (76.60)5 (10.64)5 (10.64)1 (2.13)
Control group4727 (57.45)15 (31.91)3 (6.38)2 (4.26)
χ2 value3.8996.3510.5450.000
P value0.0480.0120.4601.000
Table 4 Comparison of arthro-inflammatory indexes (mean ± SD)
Timing
Group
Number of cases
RF (U/mL)
CRP (mg/L)
ESR (mm/h)
BeforetreatmentStudy group47161.39 ± 15.0634.10 ± 6.9980.71 ± 7.11
Control group47158.91 ± 12.7932.63 ± 7.2978.65 ± 6.70
t value0.8610.9981.446
P value0.3920.3210.152
AftertreatmentStudy group4755.61 ± 6.1311.43 ± 3.5929.60 ± 5.56
Control group4773.04 ± 9.2315.07 ± 4.0636.64 ± 6.10
t value10.7854.6055.848
P value0.0000.0000.000